^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Squamous Cell Skin Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.
Source:
Title:
Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Excerpt:
...Safety profile (NCI CTCAE v4.0)`RR in PD-L1-positive patients`Disease Control Rate using RECIST and modified RECIST v.1.1`RR using modified RECIST 1.1`RR using RECIST and modified RECIST v.1.1`Best RR using RECIST and modified RECIST v.1.1`Overall Survival (OS)`Progression Free Survival by RECIST 1.1 and modified RECIST 1.1`Duration of response (DOR) by RECIST 1.1 and modified RECIST 1.1`Duration of control by RECIST 1.1 and modified RECIST 1.1`Time to disease progression by RECIST 1.1 and modified RECIST 1.1...
Trial ID:
Source:
Title:
Pembrolizumab Monotherapy as First-Line Treatment for Patients With Unresectable Cutaneous Squamous Cell Carcinoma
Published date:
08/11/2020
Excerpt:
An expansion cohort of 18 patients was added to power the study to evaluate the week 15 objective response rate difference between PD-L1–positive and PD-L1–negative patients....Objective response was observed in 55% of 42 patients with PD-L1–positive disease at baseline vs 17% of 12 patients with PD-L1–negative disease (P = .02).
